Shanghai Blue Regale Medical Technology Secures Tens of Millions RMB in Pre-A Funding to Advance Special Medical Purpose Formula Foods

VCBeat (WeChat ID: vcbeat) has learned that on March 10, Shanghai Languo Medical Technology Co., Ltd. successfully completed its Pre-A round of financing, raising tens of millions of yuan. The funds raised will be used for the company’s product research and development, innovation, factory construction, equipment improvement, and sales channel establishment.This round of financing was jointly invested by Taiyu Ankang and related industrial capital, with Chana Capital serving as the financial advisor.。

Shanghai Languo Medical Technology Co., Ltd. is a company focused on “Foods for Special Medical Purposes"andNovel Functional Foodsa sci-tech enterprise dedicated to providing high-quality, professional nutritional support for patients and special populations, aiding their recovery and enhancing their quality of life.

In terms of management and technical talent, Shanghai Languo Medical Technology Co., Ltd. boasts a robust team. It has established a food and nutrition R&D team led by Ms. Zhu Beiwei, an academician of the Chinese Academy of Engineering, as well as a high-caliber production and quality management team within the industry. Additionally, the company has founded the Institute of Clinical Nutrition and Health Foods. Meanwhile, Shanghai Languo engages in deep collaborations with Jiangnan University, West China Hospital, Xijing Hospital, and Shanghai International Medical Center to conduct clinical nutrition research and build an integrated platform for industry-academia-research translation.

In terms of R&D facility configuration, Shanghai Languo Medical Technology Co., Ltd. operates two production bases for foods for special medical purposes (FSMP) in Qingdao and Kunshan. These bases feature high-tech, intelligent production workshops and internationally standardized laboratories with comprehensive nutritional testing capabilities.

At the product level, Shanghai Languo has established a comprehensive and distinctive portfolio in the sector of foods for special medical purposes (FSMP), with multiple products progressing smoothly through the regulatory approval process. Meanwhile, its brand “Le Wuyou” has gained significant market traction due to promising clinical study results across multiple hospitals. In addition, its cross-border e-commerce product “Ni Mei Ni” NMN has also attracted a large and loyal customer base.

Dr. Ji Tianrong, Taiyu Ankang“Languo Medical boasts a team with extensive operational experience and resources in the field of nutritional health. Its academician team has accumulated a substantial portfolio of patents and technologies in food technology and processing, a series of which have been transferred to the company. Languo Medical will launch a range of products to break the situation where multinational corporations monopolize over 90% of the domestic market share for foods for special medical purposes (FSMP). By providing diverse and cost-effective FSMP options to meet the specific nutritional needs of different patient populations, the company aims to benefit patients across China.”

The foods for special medical purposes (FSMP) industry is currently in its early stages of development in the Chinese market. In recent years, heightened national attention to clinical nutrition and FSMP has driven the refinement of relevant policies, addressed the urgent clinical needs for specialized nutrients or dietary interventions among patients with specific disease states, and fostered the growth of domestic nutrition-related talent. Consequently, the FSMP market is poised to become a significant growth segment within the broader health and wellness industry.

Taiyu Ankang, backed by the publicly listed Tigermed, was jointly established by Taiyu Investment—a subsidiary of Tigermed with medical expertise and professional equity investment management experience—and Zhongshi Ankang, a leading nutritional health CRO enterprise with international vision and practical experience in the health food sector. The firm focuses on equity investments in early-stage and growth-stage companies within the nutritional health sector. The management team possesses deep industry backgrounds in pharmaceuticals and nutritional health, extensive industry resources, and rich venture capital experience. Team members have completed financing and investment transactions totaling over one billion RMB and executed equity investments in more than 40 projects. The nutritional health investment portfolio includes outstanding enterprises with independent intellectual property rights, such as Weikang Biology (probiotics production and R&D), Ping’an Gaoke (prebiotics), and Jinkang Hexin (active folic acid). By empowering portfolio companies and fully leveraging Tigermed’s and Zhongshi Ankang’s strengths in pharmaceutical and nutritional health CRO services, Taiyu Ankang aims to create value for the development of China’s nutritional health industry and contribute to public health.